Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.
Dive into The Register's online archive of incisive tech news reporting, features, and analysis dating back to 1998 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results